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OBJECTIVE — Current state-of-the-art artiﬁcial pancreas systems are either based on tradi-
tional linear control theory or rely on mathematical models of glucose-insulin dynamics. Blood
glucose control using these methods is limited due to the complexity of the biological system.
The aim of this study was to describe the principles and clinical performance of the novel
MD-Logic Artiﬁcial Pancreas (MDLAP) System.
RESEARCH DESIGN AND METHODS — The MDLAP applies fuzzy logic theory to
imitate lines of reasoning of diabetes caregivers. It uses a combination of control-to-range and
control-to-targetstrategiestoautomaticallyregulateindividualglucoselevels.Feasibilityclinical
studies were conducted in seven adults with type 1 diabetes (aged 19–30 years, mean diabetes
duration 10  4 years, mean A1C 6.6  0.7%). All underwent 14 full, closed-loop control
sessions of 8 h (fasting and meal challenge conditions) and 24 h.
RESULTS — The mean peak postprandial (overall sessions) glucose level was 224  22
mg/dl. Postprandial glucose levels returned to 180 mg/dl within 2.6  0.6 h and remained
stable in the normal range for at least 1 h. During 24-h closed-loop control, 73% of the sensor
values ranged between 70 and 180 mg/dl, 27% were 180 mg/dl, and none were 70 mg/dl.
There were no events of symptomatic hypoglycemia during any of the trials.
CONCLUSIONS — The MDLAP system is a promising tool for individualized glucose con-
trol in patients with type 1 diabetes. It is designed to minimize high glucose peaks while
preventing hypoglycemia. Further studies are planned in the broad population under daily-life
conditions.
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T
he core of the ideal artiﬁcial pan-
creassystemisthecontrolalgorithm
that automatically modulates insu-
lin delivery (and optionally other hor-
mones) according to measured glucose
levels (1). Current state-of-the-art control
algorithms for clinical use are based on
either traditional linear control theory or
crisp mathematical models of glucose-
insulin dynamics. The most common
ones are the proportional-integral-
derivative control (2) and the model pre-
dictive control (3–6). However, the
nonlinearity,complexity,anduncertainty
of the biological system, along with the
inherent delay and deviation of the mea-
suringdevices,makeitdifﬁculttocharac-
terize the model and correctly evaluate
the physiological behavior of the individ-
ual patient (2–4,6). In addition, because
the published state-of-the-art control al-
gorithmsarenotamenabletomultiplein-
puts and multiple outputs, the measured
blood glucose level is the only input in
most of them, and insulin delivery is the
only output.
To deal with these challenges, we de-
veloped the novel MD-Logic Artiﬁcial
Pancreas (MDLAP) System. The MDLAP
appliestheprinciplesoffuzzylogictheory
to imitate the line of reasoning of diabetes
caregivers. This reasoning is based on
medical knowledge and traditional treat-
ment. By taking the individual subject’s
treatment management into account, the
MDLAP can accurately adjust the control
parameters and overcome inter- and in-
trapatient variability.
Fuzzy logic is the science of reason-
ing, thinking, and inference that recog-
nizes that not everything is true or false in
the real world. In fuzzy logic, the correct-
nessofanystatementbecomesamatterof
degree. The main elements of the fuzzy
logic controller are fuzzy sets of multiple
inputs and single or multiple outputs,
fuzzy rules structured according to the
form of IF (input)–THEN (output) and
methods of “fuzziﬁcation” and “defuzziﬁ-
cation” to evaluate the fuzzy rule output
based on the input (7,8). Several groups
have proposed closed-loop systems using
a fuzzy logic controller for the manage-
mentofdiabetes(9–11),buttothebestof
our knowledge, none has been clinically
tested and validated. This article de-
scribes the principles underlying the
MDLAP system, its components and con-
trolstrategies,andtheresultsoffeasibility
clinical trials.
RESEARCH DESIGN AND
METHODS
MDLAP system
The MDLAP system is a full closed-loop
system (i.e., insulin is administered ac-
cording to the glucose readings in a fully
automated manner without information
on the size or time of meals). To imitate
the reasoning of diabetes caregivers, the
MDLAP system was designed using tradi-
tional treatment principles.
The MDLAP system uses an individ-
ual patient’s treatment management,
which includes the patient’s physical
characteristics, insulin delivery regimen
(insulin basal plan and insulin correction
factor), and insulin pharmacodynamic
parameters. The treatment management
is extracted from prerecorded data, in-
cluding subcutaneous continuous glu-
cose sensor (CGS) readings, glucometer
measurements, insulin treatment, and ac-
tivitydiary,thatwererecordedduringthe
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home (i.e., home care).
The system applies a combination of
two control strategies: control to range
and control to target. The control-to-
range strategy is implemented in the con-
trol-to-range module (CRM), which aims
at bringing the patient’s glucose levels
intothedesiredrange.TheCRMisafuzzy
logic controller that uses treatment rules
that were phrased in collaboration with
the medical staff. The declared goal of the
rules was to keep the glucose levels stable
withinthe80–120mg/dlrange.Therules
use four inputs that are calculated from
CGS readings: past and future glucose
trendaswellascurrentandfutureglucose
levels. Each rule has two outputs: 1)
change in basal rate and 2) portion of in-
sulin bolus (in percentage from the pa-
tient’sbasalplanandthecalculatedbolus,
respectively).
The control-to-target module (CTM)
aims to bring the patient’s glucose to a spe-
ciﬁc target level. To reach the ﬁnal dosing
recommendation, the CTM takes into con-
sideration the 1) recommendation of the
CRM(inpercentage),2)thepredeﬁnedglu-
cose target level, 3) insulin dosing regimen
history, and 4) safety constraints related to
the insulin pharmacodynamics. Since the
MDLAPisafullclose-loopsystem,theCTM
uses a detector in order to identify special
glucose dynamics indicative of a sign of
events that require special treatment, such
as meals. As a result, it adjusts the dosing
accordingly.
Both the patient’s treatment manage-
ment and the performance of the control-
ler are adjustable, making it easier for the
systemtodealwithinter-andintrapatient
variability. Detailed descriptions of the
system components are provided in the
online appendix (available at http://care.
diabetesjournals.org/cgi/content/full/
dc09-1830/DC1).
Clinical studies
The studies were designed as pilot pro-
spective trials. The study group consisted
of seven patients with type 1 diabetes at-
tending the National Center for Child-
hood Diabetes of Schneider Children’s
MedicalCenterofIsrael.Inclusioncriteria
wereage18years,diseasedurationofat
least1year,andtreatmentwithaninsulin
pump for at least 6 months. Patients with
a concomitant disease affecting metabolic
control or another medical condition that
could compromise their safety during the
trial were excluded, as were patients with
a known or suspected allergy to the trial
products or who had participated in an-
other study of drugs that could affect
glucose measurements or glucose man-
agement. The study was approved by the
institutional ethics committee. All sub-
jects signed an informed consent form.
Prior to the closed-loop sessions, the
patients’ demographic data, diabetes his-
tory,andothersigniﬁcantmedicalhistory
were recorded, in addition to height,
weight, and A1C level (Table 1). The pa-
tients wore a CGS (Freestyle Navigator,
Abbott Diabetes Care, Alameda, CA; or
STS-Seven System, DexCom, San Diego,
CA) and recorded their meals and physi-
cal activities for 3–5 consecutive days.
These data and corresponding insulin
doses (downloaded from the insulin
pump) were used to formulate the pa-
tients’treatmentmanagementforapplica-
tion in the MDLAP system.
A short-acting insulin analog (No-
voRapid; Novo Nordisk, Bagsvaerd, Den-
mark) was used in the clinical trials. The
CGS readings were entered (automati-
cally or manually) into the MDLAP sys-
temevery5min,andthesystemprovided
an insulin dose recommendation after
eachentry.Thecontroltorangewassetat
90–140 mg/dl and the control to target at
110 mg/dl. The clinical trials lasted 8 or
24 h of closed-loop control. Each clinical
session was supervised by a diabetologist
whohadtoapproveanytreatmentrecom-
mendation before it was automatically or
manually delivered by the pump to the
patient. Reference blood glucose levels
were measured by the YSI 2300 STAT
Plus (YSI, Yellow Springs, OH) every 30
min. Carbohydrate was administered
when the reference blood glucose level
dropped below 70 mg/dl.
8-h closed-loop sessions. The 8-h
closed-loop sessions were conducted in
the resting state under two conditions:
fasting or meal. The subject’s insulin
pump was replaced by the research insu-
linpump(OmniPodInsulinManagement
System; Insulet, Bedford, MA; or Min-
iMed Paradigm 722 Insulin Pump,
Medtronic, Northridge, CA). In the fast-
ing closed-loop condition, subjects ar-
rived to the clinic in the morning (usually
0800 h) after an overnight fast and were
instructed to measure their blood glucose
when they woke up (usually 0630 h). If
the level was 120 mg/dl with no hypo-
glycemia, they were asked to eat one to
twoslicesofbread.Intheclosed-loopses-
sions with meal challenge, patients ar-
rived to the clinic after about an 8-h fast
and consumed a mixed meal with a car-
bohydrate content of 40–60 g.
24-h closed-loop sessions. Two 24-h
closed-loop visits were conducted. The
two subjects who participated in the 24-h
sessions were the ﬁrst subjects who com-
pleted four short sessions (8 h) and were
willing to participate in this session.
There were no other criteria for choosing
subjects for the 24-h session. Subjects ar-
rived at the clinic in the afternoon after a
fast of at least 3 h. The subject’s insulin
pump was replaced with the OmniPod
CSII, which includes a commercial Pod
and an engineering PDM (Insulet) that
can communicate in real time with a per-
Table 1—Subject characteristics
Subject
no.
Age
(years)
Gender
(female/male)
BMI
(kg/m
2) A1C (%)
Disease
duration (years)
Means  SD of
blood glucose level
(mg/dl)*
IU   kg
1  
day
1
1 30 Female 22.9 5.9 19 113  54 0.72
2 23 Male 21.2 7 8 120  35 0.59
3 22 Female 26.5 6.2 8 126  44 0.63
4 25 Female 22.4 5.4 8 151  66 0.72
5 23 Male 20.0 7.1 14 143  48 0.72
6 19 Female 19.5 7.4 5 137  49 1.04
7 25 Female 19.8 7.1 10.5 119  43 1.08
*As measured at home by CGS.
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tion with the insulin pump was
conducted using the Artiﬁcial Pancreas
Software (APS) version 2.5, developed by
Dassau et al. (13). Three standard mixed
mealswereconsumedat1930,0800,and
1300 h, based on the patient’s regular
diet. The estimated carbohydrate content
foreachmealwas17.5–70g.Eachpatient
slept for 7–8 h at night during the study.
Data analysis of control performances.
To examine the control performances of
theMDLAPsystemduringthe8-hclosed-
loop sessions, we focused on two param-
eters: glucose excursion and degree of
stabilization. Glucose excursion is deter-
mined by the peak postprandial glucose
level and the time from initiation of
closed-loop control to return of the glu-
cose level to 180 mg/dl. Stable glucose
levels were deﬁned as a change of 10
mg/dl for a period of at least 30 min. The
time from initiation of closed-loop con-
trol or mealtime until the stable state was
attained, and the average glucose levels at
the stable state, were calculated.
In addition, we compared 24-h
closed-loop control to the patient’s home
care. The percentage of glucose readings
within,above,andbelowtherangeof70–
180mg/dlwasdetermined.Thedatasetof
home care included sensor readings from
the 3-day period prior to the 24-h closed-
loopsession.Controlvariabilitygridanal-
ysis (CVGA) (14) served as an auxiliary
outcome measure. The CVGA is a graph-
ical representation of the minimum/
maximum glucose values over a certain
time period. The CVGA is divided into
nine rectangular zones that are associated
with different qualities of glycemic regu-
lation. For example, accurate control (A
zone) means that the minimum glucose
levelisbetween90and110mg/dlandthe
maximum glucose level is between 110
and 180 mg/dl. Other zones are benign
controldeviation(lowerB,B,andupperB
zones), overcorrection of hypoglycemia/
hyperglycemia zones (lower C and upper
C), failure to deal with hypoglycemia/
hyperglycemia zones (lower D and upper
D), and erroneous control (E zone). In
this analysis, the home care dataset in-
cluded sensor readings from a period of
9–16 days. CVGA was performed over
two time periods: 24 h and overnight
(0000–0800 h).
RESULTS— During all of the experi-
ments, our diabetes physicians approved
each and every one of the MDLAP system
treatment suggestions. Table 2 summa-
rizes the results of the 8-h feasibility clin-
ical studies under fasting and meal
challenge conditions. Two sessions were
excluded from the analysis due to techni-
cal problems with the insulin pump. In
the ﬁrst instance, there was an occlusion
in the insulin pump tubing, and in the
second, the patient accidentally adminis-
trated insulin in addition to the insulin
that was administrated by the MDLAP
system.
Two 24-h closed-loop sessions were
conducted with subjects 1 and 2 (Table
1). During the night, glucose levels
ranged between 80 and 160 mg/dl, with a
nadir of 93 mg/dl for subject 1 and 80
mg/dl for subject 2. Figure 1A shows an
example of a 24-h closed-loop session of
subject 1. Glucose levels peaked at 260
mg/dlafterdinner,190mg/dlafterbreak-
fast, and 210 mg/dl after lunch. The cor-
respondingvaluesforsubject2were221,
211, and 219 mg/dl. Between meals, glu-
cose levels returned to 180 mg/dl
within a mean of 2.7  0.8 h for both
subjects.
Mean peak postprandial glucose level
for overall sessions (8 and 24 h) was
224  22 mg/dl, and glucose level re-
turned to 180 mg/dl at a mean interval
of 2.6  0.6 h. Mean time to stabilization
was 4  1 h. Performance analysis of the
CTM detection algorithm shows that the
overall mean detection time was 23 min
after meal consumption.
Based on our control performances
analysis(see RESEARCH DESIGN AND METHODS),
glucose control was found to be better
during the MDLAP-regulated 24-h
closed-loop sessions than during the pre-
studyhomecare.Seventy-threepercentof
the sensor values measured 70–180
mg/dl during closed-loop control com-
pared with 70.5% over the 3-day home
care period prior to the trial day. In addi-
tion, none of the sensor readings were
70 mg/dl during closed-loop control
compared with 15.3% for home care.
However, 27% of the sensor values were
180 mg/dl during closed-loop control
compared with 14.2% during home care.
On CVGA, the MDLAP maintained be-
nign control over a 24-h perspective,
whereas the subjects at home care over-
corrected and failed to manage hypogly-
cemia. During the night as well, the
MDLAP system maintained benign or ac-
curate control, whereas home care was
characterized by considerable variability.
Results of the comparison between the
MDLAP performances and home care for
subject 1 are presented in Fig. 1B and C.
No events of hypoglycemia occurred
during either the 8-h (overnight) or 24-h
closed-loop sessions. An impending hy-
poglycemiceventwasdetectedontwooc-
casions (8-h closed-loop sessions), with
glucose levels ranging between 62 and 65
mg/dlfor10min.Althoughthesubjects
did not experience any symptoms of hy-
poglycemia, our physician decided to ad-
minister 15 g of fast carbohydrate for
safety reasons.
CONCLUSIONS — The present fea-
sibility study demonstrated the use of
MDLAPtofullyclosetheloopbetweenan
externalsubcutaneousglucosesensorand
insulin pump in adults with type 1
diabetes.
The MDLAP incorporates the fuzzy
logic theory as applied to the patient’s
medical and diabetes history and treat-
ment proﬁle. The MDLAP applies tradi-
Table 2—Average and range results from 8-h closed-loop sessions
Average Range
Fasting sessions (n  6, 9 sessions)
Blood glucose at the beginning of the closed-loop
session (mg/dl)
237 178–300
Time to 180 mg/dl from system connection (h) 2.13 0.5–4.43
Time to stable blood glucose levels (h) 4.4 2.3–6.75
Blood glucose level at stabilization (mg/dl) 112 77–155
Meal challenge sessions (n  2, 3 sessions)
Blood glucose at the beginning of the closed-loop
session (mg/dl)
96 70–138
Peak postprandial blood glucose level (mg/dl) 234 211–251
Time to 180 mg/dl from meal onset (h) 2.56 2.18–3
Time to stable blood glucose levels (h) 3.43 3–4.3
Blood glucose level at stabilization (mg/dl) 102 70–134.5
Closed-loop system in type 1 diabetes
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combined control-to-range and control-
to-target strategies in order to achieve the
clinical goals of glucose control. To the
bestofourknowledge,thisistheﬁrsttime
that clinical diabetes treatment logic has
been transformed into an automatic
closed-loop system and tested in human
subjects.
In our pilot studies, the time needed
for stabilization of glucose levels within
the desired range after meal consump-
tions for overall sessions was somewhat
extended, as expected. It is noteworthy
that full closed-loop systems have an in-
herent deﬁciency for managing postmeal
glucose excursion relative to the tradi-
tional home care. While the patient is re-
quired to inject bolus insulin before each
meal in traditional home care, the closed-
loop system depends on the detection of
changes in blood glucose levels to recog-
nize a meal event and, therefore, an in-
habitant delay in insulin delivery is
mandatory. To keep postprandial levels
closer to the normal range, the closed-
loop system needs to include an effective
meal detection algorithm as well as a con-
trol strategy dedicated to treat meals. We
believe that a fuzzy logic controller is
most suitable for coping with the latter
need, since it is modular and allows ag-
gregation of different and independent
treatment modes (e.g., it can incorporate
a separate module that treats fasting peri-
ods and another one that treats meals).
Another advantage of the fuzzy logic con-
troller over the currently tested control-
lers is its ability to intuitively implement
different types of outputs on the same
control platform (e.g., insulin and
glucagon).
Figure 1—Example of 24-h closed-loop session results conducted with subject 1. A: Glucose trace and the insulin treatment during the 24-h
closed-loop trial with subject 1. The top graph shows the CGS readings (black line), reference YSI measurements ( ), and the meal times (Œ). The
bottomgraphshowstheinsulintreatmentdeliveredbytheMDLAP(horizontallinebasalrate,verticallineswithFinsulinboluses).B:Control
variabilitygridanalysisoveratimeperiodof24hforsubject1.C:Controlvariabilitygridanalysisovernight(0000–0800h)forsubject1.Thenine
zones of the CVGA are associated with different qualities of glycemic regulation: A, accurate control; lower B, benign deviations into hypoglycemia;
B, benign control deviations; upper B, benign deviations into hyperglycemia; lower C, overcorrection of hypoglycemia; upper C, overcorrection of
hyperglycemia; lower D, failure to deal with hypoglycemia; upper D, failure to deal with hyperglycemia; and E, erroneous control. In both ﬁgures,
the circles represent the minimum/maximum glucose level taken from the relevant time period glucose readings during home care and the rectangles
indicate the levels during the MDLAP-regulated closed-loop session. BG, blood glucose.
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hypoglycemia during our feasibility clin-
ical trials. Moreover, glucose levels were
maintained in the near-normal range
(80–160 mg/dl) at night. There was a
short incident of impending asymptom-
atichypoglycemiaintwoofthe14closed-
loop sessions. It is important to mention
that the MDLAP made treatment sugges-
tions, which were judged as appropriate
andapprovedbythediabetesphysicianin
charge.
The main objective of this study was
toevaluatethefeasibilityoftheMDLAPto
provide good glucose control under the
conditions that were studied. Since it is a
seven-patient pilot study, there is no con-
trol group. The performances of the sys-
tem were evaluated using objective and
appropriate parameters. Patients with
well-controlled type 1 diabetes were se-
lected to participate in this study since
they were usually compliant with the
studydemandsand,therefore,weremore
suitable for a feasibility study and also
since we wanted to compare the capabil-
ities of the system to the patients’ self-
regulated control at home. We used the
percentage of glucose readings in differ-
ent ranges as well as CVGA to provide the
reader with qualitative comparisons be-
tween the MDLAP’s glucose control and
the patient’s home glucose control. The
close-loop sessions were conducted in
conditions that were very different to
those in the subject’s home, precluding a
statistical analysis between the two
settings.
Inconclusion,theMDLAPsystemisa
promising tool for individualized glucose
control of patients with type 1 diabetes,
with the ultimate aim of minimizing high
glucose peaks while preventing hypogly-
cemia. The MDLAP is a potential tool to
overcomethreateningnocturnalhypogly-
cemia. The MDLAP system allows the in-
corporation of a learning algorithm for
automatic analysis of control perfor-
mances against intrapatient variances in
the glucose/insulin dynamics, with ad-
justments of the control parameters ac-
cordingly for further improvement of its
performance. Further studies in larger
populationsunderordinarydailylifecon-
ditions are needed.
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